Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02841241 · ClinicalTrials.gov registry record · Phase 2
Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia
A Phase 2 study, sponsored by Intermountain Health Care.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02841241 is a Phase 2 study that has completed, run by Intermountain Health Care. The registered enrollment target is 7 participants.
The verdict
NCT02841241, a Phase 2 study, has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a prospective, single arm, "roll-in" study of esmolol infusion for patients with septic shock with persistent tachycardia after adequate intravenous volume expansion. The study will evaluate the adequacy and efficiency of study protocols for the anticipated, main ECASSS study, which will have a separate entry in clinicaltrials.gov.
Interventions
- DRUG Esmolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02841241
The ClinicalTrials.gov registry entry for NCT02841241 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Esmolol is the first listed.
NCT02841241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02841241 about?
NCT02841241 is a clinical study titled "Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia". This is a prospective, single arm, "roll-in" study of esmolol infusion for patients with septic shock with persistent tachycardia after adequate intravenous volume expansion. The study will evaluate the adequacy and efficiency of study protocols for the anticipated, main ECASSS study, which will hav...
What is the current status of trial NCT02841241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-04. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02841241?
The interventions under investigation include: Esmolol (DRUG).
Who is sponsoring clinical trial NCT02841241?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.